Substudy of the the CANTOS Trial (Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated Hs-CRP; CACZ885M2301)
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Canakinumab (Primary)
- Indications Cardiovascular disorders; Myocardial infarction
- Focus Therapeutic Use
- 01 Oct 2018 Status changed from active, no longer recruiting to completed.
- 14 Sep 2017 Planned End Date changed from 1 Sep 2018 to 1 Nov 2018.
- 14 Sep 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Nov 2018.